Psikotik bozukluk tanılı hastaların taburculuk sonrası tedavi uyumları

Amaç: Tedavi uyumu psikotik bozukluklarda hastalık gidişini belirleyen en önemli değişkenlerden birisidir. Bu çalışmada yatarak tedavi gören psikotik bozukluk hastalarının taburculuk sonrası dönemde tedavi uyumları değerlendirilecektir. Aynı zamanda tedavi uyumlarına göre sınıflandırılan gruplar arasında da karşılaştırmalar yapılacaktır. Gereç ve Yöntem: Mevcut çalışmaya 30.06.2018-30.06.2019 tarihleri arasında yatarak tedavi gören ve hastaneden çıkış tanısı psikotik bozukluk olan 39 hasta dahil edilmiştir. Hastalar taburculuklarından sonra telefon ile aranarak mevcut durumları ile ilgili bilgi alınmıştır. Hastalarla yapılan bu görüşmede ayrıca Morisky Tedavi Uyum Ölçeği, Kısa İşlevsellik Değerlendirme Ölçeği ve Klinik Global İzlenim Ölçeği doldurulmuştur. Bulgular: Çalışmaya dahil edilen hastaların 20’sinin (% 51.3) tedavi uyumu düşük, 10’unun (% 25.6) tedavi uyumu orta ve dokuz hastanın (% 23.1) ise tedavi uyumu yüksek olarak bulunmuştur. Tedavi uyumu düşük olan hastaların taburculuk sonrası yeniden hastane yatışlarının daha sık olduğu, işlevselliklerinin daha kötü olduğu ve hastalıkları ile ilgili daha az bilgi sahibi oldukları tespit edilmiştir. Sonuç: Psikotik bozuklukta tedavi uyumundaki düşüklük hastalık seyrinin olumsuz olmasına neden olabileceği için tedavi uyumunu arttırmaya yönelik girişimler gerekebilir.

Post-discharge treatment compliance among patients with psychotic disorders

Purpose: Treatment compliance is one of the most important variables that determine the disease course in psychotic disorders. This study evaluates after discharge compliance among patients with psychotic disorder hospitalized for treatment. It also compares groups classified on the basis of their treatment compliance. Materials and Methods: Thirty-nine patients hospitalized for treatment between 30.06.2018 and 30.06.2019 and with discharge diagnoses of psychotic disorder were included in the study. Information concerning patients’ treatment compliance was elicited by telephone at least five months after discharge. The Morisky Medication Adherence Scale, the Functioning Assessment Short Test, and the Clinical Global Impressions Scale were completed during these interviews. Results: Treatment noncompliance was determined in 20 (51.3%) of the patients included in the study, partial compliancein 10 (25.6%), and total compliance in nine (23.1%). Patients with noncompliant to treatment experienced more frequent re-hospitalizations and poorer functionality, and possessed less knowledge concerning their disease. Conclusion: Since treatment noncompliance in psychotic disorder can result in an adverse disease course, interventions aimed at increasing compliance may be necessary.

Keywords:

Psychotic disorders, treatment adherence, medication non-compliance inpatients, hospitalization, antipsychotics,

PDF

___

1. American Psychiatric Association. Depressive Disorders. 5th ed. Washington, DC, American Psychiatric Association, 2013.
2. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S et al. Lifetime prevalence of psychotic and bipolar i disorders in a general population. Arch Gen Psychiatry. 2007;64:19-28.
3. World Health Organization. Adherence to long-term therapies: evidence for action 2020. Geneva, WHO, 2020
4. Demi̇rkol M , Tamam L, Evli̇ce Y, Karaytuğ MO. Adherence to the treatment in psychiatric patients. Cukurova Medical Journal. 2015;40:555-68.
5. Böke Ö, Özdin S. Tedavi uyumsuzluğu değerlendirme ve baş etme. In Şizofreni ve Diğer Psikotik Bozukluklar. (Eds: Danacı AE, Böke Ö, Saka MC, Erol A, Ulusoy Kaymak S, Türkiye Psikiyatri Derneği Yayınları 2018.
6. Dufort A, Zipursky RB. Understanding and managing treatment adherence in schizophrenia. Clin Schizophr Relat Psychoses. 2019; doi: 10.3371/CSRP.ADRZ.121218.
7. Chaudhari B, Saldanha D, Kadiani A, Shahani R. Evaluation of treatment adherence in outpatients with schizophrenia. Ind Psychiatry J. 2017;26:215-22.
8. Tham XC, Xie H, Chng CM, Seah XY, Lopez V, Klainin-Yobas P. Factors affecting medication adherence among adults with schizophrenia: a literature review. Arch Psychiatr Nurs. 2016;30:797- 809.
9. Civan Kahve A, Kaya H, Gül Çakıl A, Ünverdi Bıçakçı E, Göksel P, Göka E et al. Multiple antipsychotics use in patients with schizophrenia: Why do we use it, what are the results from patient follow-ups? Asian J Psychiatr. 2020;doi: 10.1016/j.ajp.2020.102063.
10. Cañas F, Alptekin K, Azorin JM, Dubois V, Emsley R, García AG, et al. Improving treatment adherence in your patients with schizophrenia: the STAY initiative. Clin Drug Invest. 2013;33:97-107.
11. Sajatovic M, Velligan DI, Weiden PJ, Valenstein MA, Ogedegbe G. Measurement of psychiatric treatment adherence. J Psychosom Res. 2010;69:591-9.
12. Roosenschoon B-J, Kamperman AM, Deen ML, Weeghel Jv, Mulder CL. Determinants of clinical, functional and personal recovery for people with schizophrenia and other severe mental illnesses: A cross-sectional analysis. PloS One.2019;14:e0222378.
13. García B. Functionality as a goal in the treatment of schizophrenia. Actas Esp Psiquiatr. 2002;30:312-25.
14. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986;24:67-74.
15. Yılmaz S. Psikiyatri hastalarında ilaç yan etkileri ve ilaç uyumu (Dokotraz tezi). İstanbul, İstanbul Üniversitesi. 2004.
16. Rosa AR, Sánchez-Moreno J, Martínez-Aran A, Salamero M, Torrent C, Reinares M et al. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin Pract Epidemiol Ment Health. 2007;3:5.
17. Aydemir Ö, Uykur B. Kısa İşlevsellik Değerlendirme Ölçeği’nin Türkçe sürümünün Bipolar Bozuklukta güvenilirliği ve geçerliliği. Turk Psikiyatri Derg. 2012;23:193-200.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare Publication (ADM). Rockville, MD: National Institute of Mental Health, 1976:76-338.
19. Dahlan R, Midin M, Sidi H, Maniam T. Hospitalbased community psychiatric service for patients with schizophrenia in Kuala Lumpur: a 1-year follow-up study of re-hospitalization. Asia-Pac Psychiatry. 2013;5:127-33.
20. Sharfstein SS. Goals of inpatient treatment for psychiatric disorders. Ann Rev Med. 2009;60:393-403.
21. Zhang Y, Dai G. Predictors of re-hospitalization over a two-year follow-up period among patients with schizophrenia enrolled in a community management program in Chengdu, China. Shanghai Arch Psychiatry. 2012;24:30-7.
22. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;(5):CD008016.
23. Remington G, Addington D, Honer W, Ismail Z, Raedler T, Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can J Psychiatry. 2017;62:604-16.
24. Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152:408-14.
25. Bitter I, Fehér L, Tényi T, Czobor P. Treatment adherence and insight in schizophrenia. Psychiatr Hung. 2015;30:18-26.
26. Abdel Aziz K, Elamin MH, El-Saadouni NM, ElGabry DA, Barakat M, Alhayyas F et al. Schizophrenia: Impact of psychopathology, faith healers and psycho-education on adherence to medications. Int J Soc Psychiatry. 2016;62:719-25.
27. Costa LG, Massuda R, Pedrini M, Passos IC, Czepielewski LS, Brietzke E, et al. Functioning in early and late stages of schizophrenia. Trends Psychiatry Psychother. 2014;36:209-13.
28. Schaub D, Brüne M, Jaspen E, Pajonk FG, Bierhoff HW, Juckel G. The illness and everyday living: close interplay of psychopathological syndromes and psychosocial functioning in chronic schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2011;261:85-93.
29. Sajatovic M, Ramirez LF, Fuentes-Casiano E, Cage J, Tatsuoka C, Aebi ME et al. A 6-Month Prospective Trial of a Personalized behavioral intervention + longacting injectable antipsychotic in individuals with schizophrenia at risk of treatment nonadherence and homelessness. J Clin Psychopharmacol. 2017;37:702- 7.